SCHEMBL25848268

SCHEMBL25848268

Nc1ccc(COC(=O)NCOCC(=O)O)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
HTT P42858 1/20 0.44
TPSAB1 Q15661 4/20 0.43
PRSS1 P07477 3/20 0.43
TPSD1 Q9BZJ3 1/20 0.43
TPSG1 Q9NRR2 1/20 0.43
PLAU P00749 2/20 0.42
F2 P00734 1/20 0.42
PLAT P00750 1/20 0.42
HDAC3 O15379 1/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC2 Q92769 1/20 0.41
KEAP1 Q14145 2/20 0.39
NFE2L2 Q16236 2/20 0.39
PLG P00747 1/20 0.39
CA12 O43570 2/20 0.39
CA1 P00915 2/20 0.39
CA2 P00918 2/20 0.39
CA9 Q16790 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27442140 0.83 SMN1; SMN2 (0.44) LMNASMN1; SMN2HTTTPSAB1PRSS1
SCHEMBL20467673 0.81 PRSS1 (0.54) LMNASMN1; SMN2HTTTPSAB1PRSS1
SCHEMBL24296999 0.80 TPSAB1 (0.53) LMNASMN1; SMN2HTTTPSAB1PRSS1
SCHEMBL16542351 0.79 HRH3 (0.42) SMN1; SMN2MAPTL3MBTL1
SCHEMBL20467629 0.79 HTT (0.61) LMNASMN1; SMN2HTTTPSAB1PRSS1
SCHEMBL25848262 0.79 ALDH1A1 (0.50) LMNASMN1; SMN2HTTTPSAB1PRSS1
SCHEMBL25306622 0.79 LMNA (0.44) LMNASMN1; SMN2HTTTPSAB1PRSS1
SCHEMBL21845023 0.78 TPSAB1 (0.53) LMNASMN1; SMN2HTTTPSAB1PRSS1
SCHEMBL22198338 0.76 TPSAB1 (0.48) LMNASMN1; SMN2HTTTPSAB1PRSS1
SCHEMBL29176117 0.76 PLAU (0.68) LMNASMN1; SMN2HTTTPSAB1PRSS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024138000-A1 PRODRUGS OF TOPOISOMERASE I INHIBITOR FOR ADC CONJUGATIONS AND METHODS OF USE THEREOF REGENERON PHARMACEUTICALS, INC. (US) 2024-06-27 WO disclosed
US-20230287138-A1 PROTEIN-DRUG CONJUGATES COMPRISING CAMPTOTHECIN ANALOGS AND METHODS OF USE THEREOF REGNERON PHARMACEUTICALS, INC. (US) 2023-09-14 US disclosed
WO-2023137026-A1 CAMPTOTHECIN ANALOGS CONJUGATED TO A GLUTAMINE RESIDUE IN A PROTEIN, AND THEIR USE REGENERON PHARMACEUTICALS, INC. (US) 2023-07-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230287138-A1 PROTEIN-DRUG CONJUGATES COMPRISING CAMPTOTHECIN ANALOGS AND METHODS OF USE THEREOF TGM2, QPCT, TGM3 LMNA 2985/4885SMN1; SMN2 4037/4885HTT 1727/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.